A new horizon

The future of AI in pharma and wider healthcare is unfolding right now – never has the crystal ball of science found itself so resolutely in the present. If we dare to glance at the horizon, however, we will see the dreamscape of an era-defining healthcare system and pharma industry, transformed by the stunning possibilities of AI
A new contract for integrated care

Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explain how the new GP contract will shape local joined-up systems
The digitisation of regulatory affairs

If information and process digitisation is as positively disruptive as its proponents claim, then what is the potential for transforming the management of marketing authorisation? Assuming this is considerable, what is involved in enabling practical, large-scale data management, and how can RA departments build on product data to help advance the broader business agenda?

News

View all

Final NICE guidance issued for Akcea’s Tegsedi

The drug should be available for routine use within 90 days for patients in England.

24th May 2019

GSK updates its sales rep incentives

The company implemented stricter rules in 2012 as part of a broad transparency initiative.

24th May 2019

NHS to undergo ‘ambitious’ tech overhaul

In the past three months alone, the NHS has prevented more than 21 million potential cyber attacks.

24th May 2019

AZ’ HER2 drug hits mid-stage trial endpoints

The drug has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation.

24th May 2019

LifeArc receives $1.2b in Keytruda royalties

In 2016, LifeArc sold a small proportion of its Keytruda royalty interest for $150 million to a private equity fund.

24th May 2019

Web Exclusives

View all

Outward looking UK scientists among global leaders in the fight against melanoma

Elsevier's Maria de Kleijn-Lloyd looks at UK researchers’ contribution to the fight against melanoma

Will healthcare be a casualty of the EU’s populist surge?

With EU parliament elections fast approaching, Nick Hoile, director of Government Affairs at Publicis Resolute, considers the potential impact of a more Eurosceptic climate on health.

Big pharma - come back to mental health and invest in Europe

As Mental Health Awareness Week 2019 begins (13/5/19), King’s College London Professor of Psychiatry Allan Young offers his thoughts on how a new European pharmacovigilance consortium could pave the way for new mental health drugs for UK patients.

NHS prescribing is back in the spotlight – where does tech fit?

Dr Simon Hendricks, clinical strategy lead at FDB (First Databank), is excited by the recent attention from Whitehall to improving NHS prescribing. He asks what progress is already being made, what needs to happen next, and where technology can play a role.

Magazine

View more from the latest edition

PatientFiles: psoriasis

Cyndi Lauper talks to PharmaTimes about her experiences with psoriasis

SmartPeople: Jennifer Turgiss

Jennifer Turgiss provides an insight into her role as vice president, behaviour science and advanced analytics, at Johnson & Johnson

Class of 2019

A high proportion of this year’s Drugs to Watch list address rare and orphan diseases

Mapping tumours – a new direction for cancer treatment

A team from the National Physical Laboratory (NPL) is developing a ‘Google Earth’ of cancer, revealing insights on a molecular scale to guide the development of more efficient drugs to target tumours. Josephine Bunch, principal investigator of the Rosetta project, offers an insight into this promising area of cancer research

A helping hand

Is augmented intelligence the key to achieving true digital transformation in pharma? Peter Crane outlines the need for a scientist-centric approach

A new horizon

The future of AI in pharma and wider healthcare is unfolding right now – never has the crystal ball of science found itself so resolutely in the present. If we dare to glance at the horizon, however, we will see the dreamscape of an era-defining healthcare system and pharma industry, transformed by the stunning possibilities of AI

Oncology needs talent

Pharma’s traditional R&D path is a business model under pressure. The ever-increasing demand for talented leadership in oncology is driving a need for collaboration

Sticking to it

In an age where medication adherence apps are the contemporary equivalent of ‘a pill for every ill’, a fresh approach is desperately needed to break through the oversaturated market.